4basebio (LON:4BB) Shares Down 7.7% - Should You Sell?

Key Points

• Shares fell 7.7% to GBX 485 on Wednesday from GBX 525.45 with extremely low volume (about 1 share versus a 1,521 average), and the stock is trading below its 50‑day (GBX 525.64) and 200‑day (GBX 617.86) moving averages.
• Insiders have been buying — 6,650 shares were purchased in the last 90 days (including Amy Walker 2,650 shares at GBX 586 and Hansjörg Plaggemars 1,000 shares at GBX 585), and insiders now own 12.07% of the company.
• The company has a market capitalization of £75.1M, a very high debt‑to‑equity ratio (201.47), healthy short‑term liquidity (quick ratio 3.52, current ratio 2.73), and a negative P/E of -4.90.

4basebio PLC (LON:4BB - ) shares were down 7.7% during mid-day trading on Wednesday . The stock traded as low as GBX 485 and last traded at GBX 485. Approximately 1 shares traded hands during trading, a decline of 100% from the average daily volume of 1,521 shares. The stock had previously closed at GBX 525.45.

4basebio Trading Down 7.7%

The firm has a 50-day moving average of GBX 525.64 and a 200-day moving average of GBX 617.86. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The firm has a market capitalization of £75.10 million, a P/E ratio of -4.90 and a beta of 1.09.

Insider Buying and Selling

In related news, insider Amy Walker purchased 2,650 shares of 4basebio stock in a transaction that occurred on Friday, February 13th. The shares were acquired at an average cost of GBX 586 per share, for a total transaction of £15,529. Also, insider Hansjörg Plaggemars purchased 1,000 shares of 4basebio stock in a transaction that occurred on Tuesday, February 10th. The shares were bought at an average price of GBX 585 per share, for a total transaction of £5,850. Insiders have purchased a total of 6,650 shares of company stock worth $3,865,900 in the last ninety days. 12.07% of the stock is owned by insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.